Lantern Pharma announced that Chief Executive Officer and President Panna Sharma will present at the 7th Glioblastoma Drug Development Summit in Boston in February 2026. During a Day Two presentation, Mr. Sharma will detail how the company's RADR® artificial intelligence and machine learning platform supported the development of STAR-001, a brain-penetrant therapeutic candidate. The presentation will cover insights into the candidate's mechanism of action, biomarker identification, indication selection, and novel combination strategies for aggressive central nervous system cancers such as glioblastoma and ATRT.
The announcement underscores the increasing importance of artificial intelligence in accelerating oncology drug discovery and development. Lantern Pharma's approach leverages its proprietary RADR® AI platform, which integrates hundreds of billions of data points to identify biomarkers, predict drug response, and design more efficient clinical trials. This methodology represents a significant shift from traditional drug development processes, potentially reducing the time and cost required to bring new therapies to patients with high unmet medical needs.
Glioblastoma remains one of the most aggressive and difficult-to-treat forms of brain cancer, with limited treatment options and poor survival rates. The development of brain-penetrant therapeutics like STAR-001 is particularly challenging due to the blood-brain barrier, which prevents many drugs from reaching their intended targets in the central nervous system. Lantern Pharma's AI-driven approach to identifying and developing such candidates could have important implications for patients with glioblastoma and other CNS malignancies who currently have few effective treatment alternatives.
The company's clinical-stage pipeline also includes other candidates targeting genomically defined patient populations, reflecting a broader trend toward precision oncology. By using artificial intelligence to match specific therapies with patients most likely to benefit, companies like Lantern Pharma aim to improve treatment outcomes while reducing exposure to ineffective therapies. The presentation at the Glioblastoma Drug Development Summit will provide the oncology community with insights into how these technologies are being applied to address one of medicine's most challenging therapeutic areas. More information about the company is available at https://ibn.fm/LTRN.
